Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Minerva Urology and Nephrology 2021 August;73(4) > Minerva Urology and Nephrology 2021 August;73(4):549-51

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

EDITORIAL COMMENT   

Minerva Urology and Nephrology 2021 August;73(4):549-51

DOI: 10.23736/S2724-6051.21.04605-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Renal tumors ablation

Michele MARCHIONI 1, 2, Daniele AMPARORE 3 , Alexandre INGELS 4, 5, Umberto CARBONARA 6, Angela PECORARO 3, Eduard ROUSSEL 7, Riccardo CAMPI 8, 9, on behalf of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group

1 Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, G. D’Annunzio University, Chieti, Italy; 2 Department of Urology, SS Annunziata Hospital, G. D’Annunzio University, Chieti, Italy; 3 School of Medicine, Division of Urology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy; 4 Department of Urology, APHP, Henri Mondor University Hospital, Créteil, France; 5 Biomaps, UMR1281, INSERM, CNRS, CEA, Paris Saclay University, Villejuif, France; 6 Unit of Andrology and Kidney Transplantation, Department of Emergency and Organ Transplantation-Urology, University of Bari, Bari, Italy; 7 Department of Urology, University Hospitals of Leuven, Leuven, Belgium; 8 Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy; 9 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy



inizio pagina